v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Research and development $ 4,436,543 $ 2,589,749 $ 12,690,621 $ 5,963,124
General and administrative 3,031,302 1,503,326 6,647,140 4,586,063
Total operating expenses 7,467,845 4,093,074 19,337,761 10,549,187
Income (loss) from operations (7,467,845) (4,093,074) (19,337,761) (10,549,187)
Other income (loss) 0 0 32,158 0
Interest income (loss) 1,271,370 655,473 3,902,778 2,033,087
Net income (loss) (6,196,475) (3,437,601) (15,402,825) (8,516,099)
Other comprehensive income (loss):        
Foreign currency translation gain (loss), net (575) (116) (249) (3,963)
Unrealized gain (loss) on investments, net 4,491 (65,763) (35,907) (20,331)
Comprehensive income (loss) $ (6,192,559) $ (3,503,480) $ (15,438,981) $ (8,540,393)
Net income (loss) per share:        
Basic and diluted (in dollars per share) $ (0.72) $ (0.48) $ (1.8) $ (1.21)
Weighted average shares outstanding:        
Basic and diluted (in shares) [1] 8,561,371 7,123,849 8,546,516 7,036,937
[1] Pre-funded warrants outstanding during the three and nine months ended September 30, 2026 and 2025, are exercisable at a nominal price and are considered, in substance, equivalent to outstanding common stock. Accordingly, such pre-funded warrants have been included in the calculation of weighted-average shares of common stock outstanding for purposes of basic and diluted net income (loss) per share.